IP Library Granted Patent US 8,581,005
Granted Patent B2
US 8,581,005 · App. 13/263,083 · Granted Nov 12, 2013

Mitochondrial inhibitors to treat human disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,581,005
App. No.
13/263,083
Granted
Nov 12, 2013
Kind
B2
Abstract

The present invention relates to inhibitors of mitochondria-associated, granulocyte-macrophage colony stimulating factor signaling molecule (Magmas), and related compositions and uses thereof.

Claims (24)

1. A compound of formula (I):

wherein A is

where “a” represents the point of attachment of A to the ring structure of formula (I) and

where R is H, aliphatic, aromatic or heterocyclic; and

wherein D is

where “d” represents the point of attachment of D to the carbon atom of C═O of formula (I); where R 1 , R 2 , R 3 , R 4 and R 5 are independently H, alkyl, aryl, phenyl, heteroaryl, arylalkyl, heterocyclic, alkenyl, allene, Br, Cl, I, F, OH, NO 2 , OCH 3 , OC 2 H 5 , O-alkyl, SH, S-alkyl, NH 2 , or NH-alkyl; and where R 6 is C, O or S;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 having the formula:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 having the formula:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 having the formula:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein R═H.

6. The compound of claim 1 , wherein alkyl is C1-C3 alkyl.

7. The compound of claim 1 , wherein one or more of R 1 , R 2 , R 3 , R 4 and R 5 is H.

8. The compound of claim 1 having the structure:

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , wherein the compound is labeled with a detectable marker.

10. The compound of claim 9 , wherein the detectable marker is a radioactive marker.

11. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

12. A method for detecting the expression of mitochondria-associated, granulocyte-macrophage colony stimulating factor signaling molecule (Magmas) in a tissue comprising contacting the tissue with the labeled compound of claim 9 .

13. A method for inhibiting mitochondrial activity in a cell or tissue or for inhibiting metabolic activity in a cell or tissue comprising contacting the cell or tissue with the compound of claim 1 .

14. A method of imaging ischemic injury in a subject comprising administering to the subject the compound of claim 9 .

Assignments (2)
CHANGE OF NAME Recorded Oct 19, 2015
From: COM AFFILIATION, INC.
To: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Reel/Frame 036888/0682 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2015
From: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
To: COM AFFILIATION, INC.
Reel/Frame 036873/0672 →